Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium can target key mechanisms underlying disease progression in multiple sclerosis (MS), including acute and chronic inflammation, as well as Epstein-Barr virus (EBV) reactivation, according to new trial data. The Phase 2 CALLIPER trial (NCT05054140)Â investigated vidofludimus calcium against a placebo in people with progressive forms of MS. Immunic presented […]
The post ACTRIMS 2026: Vidofludimus calcium targets key MS mechanisms, data show appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com